July 2023
White House Reaction to Israeli Parliament Vote: We Support Broader Consensus
The White House expressed concern over the Israeli Knesset's approval of judicial reforms proposed by Netanyahu, emphasizing the need for broader consensus in a democratic…
Judicial Reforms in Israel; Voting Begins, Herzog Describes Situation as 'Emergency'
The Knesset has begun voting on controversial judicial reforms proposed by Netanyahu, amidst significant public protests and political turmoil. President Herzog describes the situation as…
Government Refuses to Implement It; Increase in Disability Benefits
Disabled individuals in Iran are protesting the government's failure to implement Article 27 of the Disability Support Law, which mandates increased benefits. Activists report that…
Joe Biden Appoints a Woman Admiral to Command the U.S. Navy
President Joe Biden has appointed Admiral Lisa Franchetti as the first female commander of the U.S. Navy, despite opposition from Republican Senator Tommy Tuberville. This…
Israeli President Warns Kamala Harris About Iran During Meeting
Israeli President Isaac Herzog met with U.S. Vice President Kamala Harris to discuss the threats posed by Iran, emphasizing that Iran's nuclear ambitions are not…
Before Herzog's Speech in Congress; Biden and Netanyahu Discussed Iran
Joe Biden and Benjamin Netanyahu discussed their ongoing tensions and Iran's nuclear program in a phone call ahead of a scheduled meeting between Biden and…
Successful Launch of India's 'Chandrayaan-3' Spacecraft; Efforts to Land on the 'Dark Side' of the Moon
India successfully launched its 'Chandrayaan-3' spacecraft with the goal of landing on the moon's dark side. This mission follows a previous unsuccessful attempt four years…
Israeli Defense Minister Travels to Azerbaijan to Strengthen Strategic Relations
Israeli Defense Minister Yoav Gallant is visiting Azerbaijan to strengthen strategic relations amid deteriorating ties between Iran and Azerbaijan. This visit is significant as it…
Transformation in Alzheimer's Treatment; U.S. Issues Approval for 'Lecanemab'
The U.S. FDA has approved Lecanemab, a new Alzheimer's drug that slows disease progression, costing about $26,050 annually. Developed by Eisai and Biogen, this drug…